Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 196

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Influence of the Angiotensin II Antagonist Valsartan on Left Ventricular Hypertrophy in Patients With Essential Hypertension

Open access
Thürmann, Petra A., Kenedi, Peter, Schmidt, Andor, Harder, Sebastian, Rietbrock, Norbert · 1998 · Circulation

Abstract

Background —Left ventricular hypertrophy (LVH) represents an independent risk factor in patients with essential hypertension. Because reversal of LVH may be associated with an improvement of prognosis, the influence of new antihypertensive compounds, such as angiotensin II AT 1 receptor antagonists, on LVH should be determined. Methods and Results —In a randomized, double-blind trial, 69 predominantly previously untreated hypertensive patients with echocardiographically proven LVH, ie, left ventricular mass index (LVMI) >134 g/m 2 in men and >110 g/m 2 in women and/or end-diastolic septal thickness >12 mm, received either the angiotensin II antagonist valsartan or atenolol for 8 months. Echocardiographic data of 58 patients were available. After 8 months of valsartan treatment (n=29), LVMI decreased from 127±23 to 106±25 g/m 2 (ratio [ R ]=0.83; 95% CI, 0.79 to 0.87; P <0.0001 versus baseline). Under atenolol (n=29), LVMI decreased to a smaller extent, from 127±25 to 117±27 g/m 2 ( R =0.92; 95% CI, 0.86 to 0.98; P =0.0082 versus baseline). The mean reduction of LVMI came to 21 g/m 2 under valsartan and only to 10 g/m 2 under atenolol ( R =0.91; 90% CI, 0.85 to 0.97 versus atenolol). Baseline mean blood pressure values were determined to be 163±12/101±6 mm Hg before treatment with valsartan and 160±14/103±6 mm Hg before atenolol treatment. After 8 months of treatment, mean blood pressure decreased to 146±13/90±7 mm Hg with valsartan and to 147±18/90±7 mm Hg with atenolol. Nine patients in the valsartan group and 8 patients in the atenolol group required additional medication with hydrochlorothiazide. Conclusions —Antihypertensive treatment with the angiotensin II antagonist valsartan for 8 months produced a significant regression of LVH in predominantly previously untreated patients with essential hypertension. The drug may be safely administered in this subset of hypertensive patients; however, the long-term benefit in terms of risk reduction has still to be evaluated in further trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.98.19.2037

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 196

Metadata

Authors
Thürmann, P. A., Kenedi, P., Schmidt, A., Harder, S., & Rietbrock, N.
Venue
Circulation
Published
1998-11-10
Volume
98
Issue
19
Pages
2037-2042
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2093934591
Cited by
196
References
2
FWCI
14.84
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Influence of the Angiotensin II Antagonist Valsartan on Left Ventricular Hypertrophy in Patients With Essential Hypertension. https://app.cochat.ai/papers/10.1161/01.cir.98.19.2037
The paper
Thürmann, P. A., Kenedi, P., Schmidt, A., Harder, S., & Rietbrock, N. (1998). Influence of the Angiotensin II Antagonist Valsartan on Left Ventricular Hypertrophy in Patients With Essential Hypertension. Circulation. https://doi.org/10.1161/01.cir.98.19.2037

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.